Diabetes Obesity and Metabolism

OCT 22, 2026 · REVIEW

How Well Are We Measuring Nausea? A Narrative Review of Patient‐Reported Outcome Gaps in GLP ‐1 Receptor Agonist Obesity Trials

Diabetes Obesity and Metabolism

ABSTRACT Across the full spectrum of major clinical trials evaluating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for obesity management, nausea consistently emerges as t

OCT 22, 2026 · JOURNAL ARTICLE

Sustained Versus Minimal GLP ‐1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes

Diabetes Obesity and Metabolism

ABSTRACT Aims To compare changes in body mass index (BMI) categories after sustained versus minimal glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) exposure in older adults wit

OCT 19, 2026 · JOURNAL ARTICLE

Beyond Drugs or Surgery: Precision and Equity in Obesity Care

Diabetes Obesity and Metabolism

Key Messages GLP‐1 receptor agonists and metabolic bariatric surgery are complementary tools in chronic obesity care, not simple substitutes. Trial efficacy, real‐world effectivene

OCT 14, 2026 · JOURNAL ARTICLE

Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Melanin‐Concentrating Hormone Receptor‐1 Antagonist RGH‐706 in Healthy and Overweight or Obese Men

Diabetes Obesity and Metabolism

ABSTRACT Aim This Phase 1 program evaluated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of the novel melanin‐concentrating hormone receptor‐1 antago

OCT 1, 2026 · JOURNAL ARTICLE

Nephroprotective Effects of the Dual GCGR / GLP ‐ 1R Agonist Survodutide in Hypertension‐Accelerated Diabetic Kidney Disease

Diabetes Obesity and Metabolism

ABSTRACT Aims Survodutide is a novel long‐acting dual glucagon (GCGR)/glucagon‐like peptide‐1 (GLP‐1R) receptor agonist currently in phase‐3 clinical development for the treatment

SEP 29, 2026 · REVIEW

Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis

Diabetes Obesity and Metabolism

BACKGROUND: Dual glucagon-like peptide-1/glucagon receptor (GLP-1/GCGR) agonists represent a novel obesity treatment class, but existing meta-analyses often conflate them with GIP-

SEP 27, 2026 · JOURNAL ARTICLE

Addendum to “The Duodenal Mucosa Plays a Key Role in Metabolic Regulation: Emerging Physiology and New Opportunities for Cell‐Directed and Barrier‐Related Interventions for the Treatment of Diabetes and Obesity”

Diabetes Obesity and Metabolism

Duodenal pulsed electric field (PEF) therapy has emerged as a clinical approach for metabolic disease only very recently, with its pivotal human evidence appearing essentially in p

SEP 17, 2026 · REVIEW

Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD: A Systematic Review and Meta‐Analysis

Diabetes Obesity and Metabolism

ABSTRACT Aims Adults with obesity are at increased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related fibrosis, but the diagnostic performance of non‐